Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8:224–233
Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky R (2014) Optimizing dosing of oncology drugs. Clin Pharmacol Ther 96:572–579
Ratain MJ, Tannock IF, Lichter AS (2021) Dose optimization of sotorasib: is the US Food and Drug Administration sending a message? J Clin Oncol 39:3423–3426
Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent S, Song X, Segal R, Mazzarello S (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142:101–107
Wood R, Mitra D, de Courcy J, Iyer S (2017) Patient-reported quality of life and treatment satisfaction in patients with HR+/HER2–advanced/metastatic breast cancer. Clin Ther 39:1719–1728
Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart M (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13:197–207
Shah M, Rahman A, Theoret MR, Pazdur R (2021) The drug-dosing conundrum in oncology-when less is more. N Engl J Med 385:1445–1447
Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J (2012) Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 9:471–478
Carlson M (2021) When the ‘Maximum Tolerable Dose’ of Cancer Treatment Isn’t Tolerable. Cure Today. https://www.curetoday.com/view/when-the-maximum-tolerable-dose-of-cancer-treatment-isn-t-tolerable. Accessed 22 March 2022
Nanda S (2021) Patient survey points to need for innovative dosing strategies in MBC. Medicine Matters. https://oncology.medicinematters.com/asco-2021/breast-cancer/patient-advocate-led-survey-innovative-drugdosing/19251100. Accessed 22 March 2022
Ratain MJ (2014) Redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol 11:503–504
Nie L, Rubin EH, Mehrotra N, Pinheiro J, Fernandes LL, Roy A, Bailey S, de Alwis DP (2016) Rendering the 3+ 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin Cancer Res 22:2623–2629
Norris DC (2017) Dose titration algorithm tuning (DTAT) should supersede ‘the’ maximum tolerated dose (MTD) in oncology dose-finding trials. F1000Research 6:112
PubMed PubMed Central Google Scholar
Subbiah V, Kurzrock R (2018) Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer 4:101–109
PubMed PubMed Central Google Scholar
Mandrekar SJ, Cui Y, Sargent DJ (2007) An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 26:2317–2330
Ratain MJ, Strohbehn GW, Tannock IF, Lichter (2021) Optimize the dose: An optimal step forward for FDA. Periodical: The Cancer Letter. 47(23): https://cancerletter.com/guest-editorial/20210611_4/. Accessed 22 March 2022
Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE (2016) Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle. Clin Cancer Res 22:2613–2617. https://doi.org/10.1158/1078-0432.Ccr-15-2643
Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. JNCI J Natl Cancer Inst 101:708–720
Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G (2018) A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42–12/BIG 2–12 SNAP trial. Ann Oncol 29:661–668. https://doi.org/10.1093/annonc/mdx772
Article CAS PubMed Google Scholar
Leonard R, Hennessy BT, Blum JL, O’Shaughnessy J (2011) Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 11:349–356
Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069–1076
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R (2020) Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 17:233–250. https://doi.org/10.1038/s41571-019-0299-9
Sheen MA, Apuri S, Ismail-Khan R (2016) Progression free survival and toxicity with dose variations of everolimus in metastatic hormone receptor positive breast cancer. J Clin Oncol 34:e12058–e12058. https://doi.org/10.1200/JCO.2016.34.15_suppl.e12058
Project Optimus. FDA
Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP (2016) Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Clin Cancer Res 22:1318–1324
Peck RW (2018) Precision medicine is not just genomics: the right dose for every patient. Annu Rev Pharmacol Toxicol 58:105–122
Blumenthal G, Jain L, Loeser AL, Pithaval YK, Rahman A, Ratain MJ, Shah M, Strawn L, Theoret MR (2021) Optimizing dosing in oncology drug development. Friends Cancer Res pp 1–14
Dreyer MS, Kacew A, Hsieh P-H, Serritella A, Knoebel RW, Nanda R, Strohbehn GW, Ratain MJ (2021) Patient out-of-pocket savings with lower-dose trastuzumab. J Clin Oncol 39:e18828–e18828. https://doi.org/10.1200/JCO.2021.39.15_suppl.e18828
(2021) Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)1 Dose comparison study. In: PR Newswire, Thousand Oaks, CA
(2020) About Us. In: Patient Centered Dosing Initiative
Loeser AL, Peppercorn JM, Burkard ME, Kalinsky K, Rugo HS, Bardia A (2021) Treatment-related side effects and views about dosage assessment to sustain quality of life: results of an advocate-led survey of patients with metastatic breast cancer (MBC). J Clin Oncol 39:1005
Loeser AL, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Maues J, McGlown S (2022) Abstract P4-10-09: patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Cancer Res 82:P4-10-09-P14-10-09
R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485–3490
Behroozian T, Milton L, Zhang L, Lou J, Karam I, Lam E, Wong G, Szumacher E, Chow E (2021) How do patient-reported outcomes compare with clinician assessments? A prospective study of radiation dermatitis in breast cancer. Radiother Oncol 159:98–105
Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953–962
Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24:3669–3676
PubMed PubMed Central Google Scholar
Veitch ZW, Shepshelovich D, Gallagher C, Wang L, Abdul Razak AR, Spreafico A, Bedard PL, Siu LL, Minasian L, Hansen AR (2021) Underreporting of symptomatic adverse events in phase I clinical trials. JNCI J Natl Cancer Inst 113:980–988
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. JNCI J Natl Cancer Inst 101:1624–1632
Mayer M (2014) Living with advanced breast cancer: challenges and opportunities. Breast 20:S12–S13. https://doi.org/10.1016/j.breast.2011.08.004
Tanay M, Armes J, Ream E (2017) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care 26:e12443
Breetvelt I, Van Dam F (1991) Underreporting by cancer patients: the case of response-shift. Soc Sci Med 32:981–987
(2014) Metastatic breast cancer landscape analysis: research report. MBC Alliance, New York, NY
Markman M (2006) Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep 10:275–278
Rao A, Cohen HJ (2004) Symptom management in the elderly cancer patient: fatigue, pain, and depression. JNCI Monogr 2004:150–157
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G (2005) New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 11:5342–5346
Mathijssen RH, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272–281
Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP (2020) Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. J Clin Oncol 38:4120–4129. https://doi.org/10.1200/jco.20.01382
Article CAS PubMed Google Scholar
Hart LL, Bardia A, Beck JT, Chan A, Neven P, Hamilton EP, Sohn J, Sonke GS, Bachelot T, Spring L, Gac FL, Hu H, Gao M, Laurentiis MD (2022) Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. J Clin Oncol 40:1017–1017. https://doi.org/10.1200/JCO.2022.40.16_suppl.1017
Xie X, Wu Y, Luo S, Yang H, Li L, Zh
留言 (0)